Vir Biotechnology and Gilead Partner on Solid Tumor T-Cell Therapies
Event summary
- Vir Biotechnology and Gilead Sciences have entered a multi-program collaboration to develop three novel PRO-XTEN® dual-masked T-cell engagers (TCEs) for solid tumors.
- Gilead will have exclusive rights to develop and commercialize the TCEs, while Vir Biotechnology will receive up to $135 million in upfront and near-term preclinical milestone payments.
- The deal includes a $90 million upfront payment, with $65 million in cash and a $25 million equity investment at a 30% premium.
- Vir Biotechnology could receive up to $1.74 billion in additional development, regulatory, and commercial milestones, along with tiered royalties on net sales.
The big picture
This collaboration underscores the growing focus on next-generation immunotherapies for solid tumors, an area with significant unmet medical needs. The deal validates Vir Biotechnology's PRO-XTEN® platform and positions Gilead to expand its oncology portfolio. The strategic partnership highlights the increasing importance of biotech collaborations in advancing complex cancer treatments.
What we're watching
- Technical Feasibility
- How Vir Biotechnology's PRO-XTEN® masking technology will perform in solid tumors, addressing current toxicity challenges.
- Commercial Potential
- Whether Gilead can successfully develop and commercialize the TCEs, given its growing oncology capabilities.
- Financial Impact
- The pace at which Vir Biotechnology realizes milestone payments and royalties, and how this affects its financial strategy.
Related topics
